Goodwin Procter attorneys recently advised the underwriters in Intercept Pharmaceuticals’ follow-on public offering of 1,000,000 shares of common stock. The underwriting syndicate was led by BofA Merrill Lynch, Citigroup, Goldman Sachs & Co. and Deutsche Bank Securities.
Intercept’s offering, which priced at $320.00 per share, included 600,000 shares sold by the company, with net proceeds of approximately $183.3 million, and 400,000 shares sold by certain institutional stockholders. Intercept, which went public in October 2012, is traded on the NASDAQ exchange under symbol “ICPT”.
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company is based in New York City (corporate) and San Diego, Calif. (development).
The Goodwin team advising the underwriters was led by partner Ilan Nissan (corporate), and included partners Duncan Greenhalgh and Chad Davis (patent) and associates Laurie Burlingame and Eric Hinz (corporate).
To learn more about Intercept’s offering, please read the company’s press release.